Dr. Jänne is the Senior Vice President for Translational Medicine at Dana-Farber Cancer Institute, a Professor of Medicine at Harvard Medical School, and the David M. Livingston, MD Chair at Dana-Farber Cancer Institute. He also serves as the Director of the Belfer Center for Applied Cancer Science at the Dana-Farber Cancer Institute. He is a thoracic medical oncologist and led the Thoracic Medical Oncology Program at Dana-Farber Cancer Institute from 2013 to 2024. After earning his MD and PhD from the School of Medicine at the University of Pennsylvania, Dr. Jänne completed his internship and residency in Medicine at Brigham and Women’s Hospital, Boston. He subsequently completed fellowship training at the Dana-Farber Cancer Institute/Massachusetts General Hospital combined program in medical oncology in 2001. In 2002 he earned a Master’s Degree in clinical investigation from Harvard University.

Dr. Jänne’s research combines laboratory-based studies with translational research and clinical trials of novel therapeutic agents in patients with lung cancer. His main research interests center around understanding and translating the therapeutic importance of oncogenic alterations in lung cancer. He has made seminal therapeutic discoveries, including being one of the co-discoverers of EGFR mutations, and findings from his work have led to the development of several clinical trials. Dr. Jänne has received several awards for his work including from the American Association for Cancer Research, the European Society for Medical Oncology, the American Society of Clinical Oncology, and the Medal of Honor from the American Cancer Society.